Although vaccines to treat nicotine and cocaine addiction are currently in clinical trials, no specific medications exist to treat dependence on (+)-methamphetamine ((+)METH)-like drugs. To address this need, these preclinical studies will facilitate the medical discovery and development of new (+)METH- conjugate vaccines (MCVs) to help patients stop using (+)METH-like drugs. These important new MCVs are expected to block or reduce (+)METH effects in patients. The discovery of medically effective MCVs will be accomplished through our well-integrated, multidisciplinary research program designed to manufacture and test MCVs. In previous preclinical studies, our group showed that 1) titer and affinity of antibodies generated against MCV are not adversely affected by continuous (+)METH use, 2) a single MCV might be used to generate high-affinity antibodies against (+)METH and (+)-amphetamine ((+)AMP), and 3) anti-(+)METH monoclonal antibodies generated from a novel MCV can be used to reduce brain (+)METH concentrations and reduce (+)METH or (+)AMP self-administration. These accomplishments substantially enhanced our scientific vision, clearly defined the project's research aims, and identified a premier MCV candidate for the for use in active immunization. Our ultimate goal is to have one or more safe, effective MCV in a human- compatible formulation ready for clinical trials within five years. To accomplish this, we have four aims.
In Aim 1, we will design, synthesize, and manufacture innovative new MCVs and carefully optimize the immunological conditions needed to achieve the best combination of antibody titer, affinity, specificity of response, and duration of action (i.e., therapeutic effectiveness).
In Aim 2, we will test the best of these MCVs in pharmacokinetic and behavioral studies designed to select MCVs that decrease penetration of (+)METH into the brain and reduce or block drug self-administration without adversely influencing withdrawal effects.
In Aim 3, safety will be determined by monitoring general animal health, measuring blood chemistries, and examining animal tissues during and after chronic vaccination.
In Aim 4, a data monitoring program based on data sets collected in Aims 1-3 will be developed and enacted with industry partner InterveXion Therapeutics to maximize the potential for expedient FDA approval. The decision to take an MCV candidate to the FDA will be made in collaboration with external advisors and NIDA, then our ongoing programmatic approach will facilitate rapid transition through clinical testing, including IND application. Achieving our goal will address the major public health problem of (+)METH dependence by blocking or reducing its effects even under challenges of binge and relapse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DA023900-04
Application #
7921670
Study Section
Special Emphasis Panel (ZDA1-MXS-M (16))
Program Officer
Chiang, Nora
Project Start
2007-09-30
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
4
Fiscal Year
2010
Total Cost
$966,958
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Pharmacology
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Stevens, Misty W; Gunnell, Melinda G; Tawney, Rachel et al. (2016) Optimization of a methamphetamine conjugate vaccine for antibody production in mice. Int Immunopharmacol 35:137-141
Hambuchen, Michael D; Carroll, F Ivy; Rüedi-Bettschen, Daniela et al. (2015) Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. J Med Chem 58:4665-77
Harris, Andrew C; LeSage, Mark G; Shelley, David et al. (2015) The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. PLoS One 10:e0118787
Peterson, Eric C; Hambuchen, Michael D; Tawney, Rachel L et al. (2014) Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages. Bioconjug Chem 25:2112-5
Hambuchen, Michael D; Rüedi-Bettschen, Daniela; Williams, D Keith et al. (2014) Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. Vaccine 32:6213-9
Rüedi-Bettschen, Daniela; Wood, Sherri L; Gunnell, Melinda G et al. (2013) Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 31:4596-602
Carroll, F Ivy; Blough, Bruce E; Pidaparthi, Ramakrishna R et al. (2011) Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 54:5221-8
Gentry, W B; Ruedi-Bettschen, D; Owens, S M (2010) Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther 88:390-3
Gentry, W Brooks; Rüedi-Bettschen, Daniela; Owens, S Michael (2009) Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin 5:206-13
Carroll, F Ivy; Abraham, Philip; Gong, Paul K et al. (2009) The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 52:7301-9